# Sirolimus in Combination With MEC in High Risk Myeloid Leukemias

> **NCT00780104** · PHASE1 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 16 (actual)

## Conditions studied

- Myeloid Leukemias
- AML
- Leukemia
- CML

## Interventions

- **DRUG:** Rapamycin, Mitoxantrone, Etoposide, Cytarabine
- **DRUG:** Rapamycin + MEC

## Key facts

- **NCT ID:** NCT00780104
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2010-01
- **Final completion:** 2010-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00780104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00780104, "Sirolimus in Combination With MEC in High Risk Myeloid Leukemias". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00780104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*